Replimune Group (NASDAQ:REPL) Trading Down 5.6% – Should You Sell?

Shares of Replimune Group, Inc. (NASDAQ:REPL) were down 5.6% on Friday . The stock traded as low as $10.99 and last traded at $10.95. Approximately 384,744 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 694,876 shares. The stock had previously closed at $11.60.

Analyst Ratings Changes

Several brokerages recently commented on REPL. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $19.43.

Replimune Group Stock Performance

The stock has a market cap of $841.77 million, a price-to-earnings ratio of -3.56 and a beta of 1.30. The company’s fifty day simple moving average is $12.67 and its two-hundred day simple moving average is $12.13. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after acquiring an additional 52,498 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the last quarter. Barclays PLC grew its position in Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after purchasing an additional 98,791 shares in the last quarter. State Street Corp increased its stake in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its position in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.